Eric Benjamin
17Patents
7h-index
30Co-inventors
66Inventor score
Filing activity: Apr 30, 1981 → Mar 10, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4382091A | Stabilization of 1-substituted imidazole derivatives in talc | Human Necessities | 53 | Expired |
| US4837239A | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins | Human Necessities | 41 | Expired |
| US4782047A | Aqueous steroid formulations for nasal administration | Human Necessities | 24 | Expired |
| US4983595A | Aqueous steroid formulations for nasal administration | Human Necessities | 22 | Expired |
| US6815424B2 | Intranasal administration of polypeptides in powdered form | Human Necessities | 22 | Expired |
| US7759386B2 | Pharmaceutical compositions of estrogenic agents | Human Necessities | 9 | Active |
| US7981424B2 | RAGE fusion proteins, formulations, and methods of use thereof | Chemistry; Metallurgy | 9 | Active |
| US7271177B2 | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions | Human Necessities | 7 | Expired |
| US7446111B2 | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions | Human Necessities | 7 | Active |
| US6521597B1 | Intranasal administration of LHRH polypeptides in powdered form | Human Necessities | 4 | Expired |
| US9198901B2 | Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof | Human Necessities | 3 | Active |
| US10292966B2 | Sustained release pharmaceutical compositions | Human Necessities | 2 | Active |
| US10463648B2 | Sustained release pharmaceutical compositions | Human Necessities | 2 | Active |
| US11179369B2 | Sustained release pharmaceutical compositions | Human Necessities | 0 | Active |
| US11935637B2 | Onboarding and total daily insulin adaptivity | Human Necessities | 0 | Active |
| US11957875B2 | Techniques and devices providing adaptivity and personalization in diabetes treatment | Human Necessities | 0 | Active |
| US12431229B2 | Medicament delivery device with an adjustable and piecewise analyte level cost component to address persistent positive analyte level excursions | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.